Health and Healthcare

Gilead Sciences : GILD

All Gilead Sciences Articles

730 Articles

Chris Lange | Jul 12, 2018 at 8:21 AM EDT

Short Sellers Back Off Major Biotechs

The June 29 short interest data have been compared with the previous report, and short interest in most of the…

Lee Jackson | Jul 11, 2018 at 9:20 AM EDT

7 Stocks to Buy Now That Will Outperform and Still Be Relevant in 2025

RBC feels these seven top companies will still be very relevant in 2025, and the goods or services they provide…

Chris Lange | Jun 27, 2018 at 9:00 AM EDT

Short Sellers Run for Cover From Major Biotechs

The June 15 short interest data have been compared with the previous report, and short interest in most of the…

Chris Lange | Jun 12, 2018 at 10:54 AM EDT

Short Sellers Up the Ante For Major Biotechs

24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The May 31 short interest data…

Lee Jackson | Jun 4, 2018 at 10:05 AM EDT

Jefferies Analysts Out With Top Stock Picks Before Big Health Care Conference

While the health care sector as a whole has had its ups and downs, there is no question that mergers…

Lee Jackson | Jun 1, 2018 at 10:30 AM EDT

Biotech and Pharmaceutical Giants Go All In With Big Data Analytics

It’s no surprise that it was only a matter of time before the usage and storage of big data and…

Chris Lange | May 25, 2018 at 9:40 AM EDT

Short Interest Remains Mixed in Major Biotechs

The May 15 short interest data have been compared with the previous report, and short interest moves in the selected…

Chris Lange | May 10, 2018 at 10:40 AM EDT

Big Biotechs Scare Off Short Sellers

The April 30 short interest data have been compared with the previous report, and short interest in most of the…

Jon C. Ogg | May 2, 2018 at 12:05 PM EDT

Analysts Show More Caution Toward Gilead’s Mystical Recovery

Gilead Science was supposed to be coming back as a company on the heels of its first major acquisition in…

Chris Lange | May 2, 2018 at 8:45 AM EDT

Why Gilead Sciences Whiffed in Q1

Gilead Sciences released disappointing first-quarter financial results late Tuesday and shares tumbled early Wednesday.

Chris Lange | May 1, 2018 at 12:05 PM EDT

Will Gilead Sciences Earnings Get a Boost From a Collaboration?

Gilead Sciences is set to report its most recent quarterly results after the markets close on Tuesday, the first since…

Chris Lange | Apr 25, 2018 at 8:40 AM EDT

Major Biotechs Face Rising Tide of Short Interest

The April 13 short interest data have been compared with the previous report, and short interest in most of the…

Chris Lange | Apr 11, 2018 at 9:05 AM EDT

Short Sellers Back Way Off Major Biotechs

The March 29 short interest data have been compared with the previous report, and short interest in most of the…

Chris Lange | Mar 27, 2018 at 9:30 AM EDT

Major Biotechs See Rising Tide in Short Interest

The March 15 short interest data have been compared with the previous report, and short interest in most of the…

Chris Lange | Mar 12, 2018 at 9:45 AM EDT

Major Biotechs: Tough Call for Short Sellers

The February 28 short interest data have been compared with the previous report, and short interest moves in the selected…

1 … 15 16 17 18 19 … 49

Gilead Sciences : GILD

All Gilead Sciences Articles

Short Sellers Back Off Major Biotechs

7 Stocks to Buy Now That Will Outperform and Still Be Relevant in 2025

Short Sellers Run for Cover From Major Biotechs

Short Sellers Up the Ante For Major Biotechs

Jefferies Analysts Out With Top Stock Picks Before Big Health Care Conference

Biotech and Pharmaceutical Giants Go All In With Big Data Analytics

Short Interest Remains Mixed in Major Biotechs

Big Biotechs Scare Off Short Sellers

Analysts Show More Caution Toward Gilead’s Mystical Recovery

Why Gilead Sciences Whiffed in Q1

Will Gilead Sciences Earnings Get a Boost From a Collaboration?

Major Biotechs Face Rising Tide of Short Interest

Short Sellers Back Way Off Major Biotechs

Major Biotechs See Rising Tide in Short Interest

Major Biotechs: Tough Call for Short Sellers

This High-Yield Emerging Funds ETF Offers International Diversification

A 71-Year-Old’s $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy’s 25% Savings Rule Actually Starts at 15%

A 71-Year-Old's $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy's 25% Savings Rule Actually Starts at 15%

This High-Yield Emerging Funds ETF Offers International Diversification

A 71-Year-Old’s $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Gilead Sciences : GILD

All Gilead Sciences Articles

Short Sellers Back Off Major Biotechs

7 Stocks to Buy Now That Will Outperform and Still Be Relevant in 2025

Short Sellers Run for Cover From Major Biotechs

Short Sellers Up the Ante For Major Biotechs

Jefferies Analysts Out With Top Stock Picks Before Big Health Care Conference

Biotech and Pharmaceutical Giants Go All In With Big Data Analytics

Short Interest Remains Mixed in Major Biotechs

Big Biotechs Scare Off Short Sellers

Analysts Show More Caution Toward Gilead’s Mystical Recovery

Why Gilead Sciences Whiffed in Q1

Will Gilead Sciences Earnings Get a Boost From a Collaboration?

Major Biotechs Face Rising Tide of Short Interest

Short Sellers Back Way Off Major Biotechs

Major Biotechs See Rising Tide in Short Interest

Major Biotechs: Tough Call for Short Sellers

This High-Yield Emerging Funds ETF Offers International Diversification

A 71-Year-Old’s $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy’s 25% Savings Rule Actually Starts at 15%

Featured Reads

A 71-Year-Old's $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy's 25% Savings Rule Actually Starts at 15%